Melvin L K Chua

List of Publications by Year in Descending Order

137 papers	4,716 citations	26 h-index	67 g-index
174 ext. papers	6,436 ext. citations	7.2 avg, IF	6.18 L-index

#	Paper	IF	Citations
137	Adolescents and young adults with cancer: Considerations from the Southeast Asian perspective.. *Pediatric Blood and Cancer*, **2022**, e29593	3	2
136	Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis.. *BMJ Open*, **2022**, 12, e044661	3	2
135	In Reply to Abbasi et al.. *International Journal of Radiation Oncology Biology Physics*, **2022**, 112, 262-263	4	
134	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. *Urologic Oncology: Seminars and Original Investigations*, **2022**, 40, 5.e1-5.e13	2.8	
133	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?. *JAMA Oncology*, **2022**,	13.4	1
132	Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211052417	5.4	9
131	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. *Journal of Clinical Oncology*, **2021**, 39, 840-859	2.2	42
130	Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. *JAMA Oncology*, **2021**, 7, 597-602	13.4	23
129	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. *Oral Oncology*, **2021**, 115, 105222	4.4	2
128	Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.. *Journal of Clinical Oncology*, **2021**, 39, 6005-6005	2.2	4
127	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. *Lancet Oncology, The*, **2021**, 22, e217	21.7	
126	Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. *Radiotherapy and Oncology*, **2021**, 160, 140-147	5.3	2
125	Immunotherapy in Head and Neck Cancer-Ready for Prime Time or More Research Needed?. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 647-650	4	
124	Reply to Colorectal cancer and COVID-19: Do we need to raise awareness and vigilance?. *Cancer*, **2021**, 127, 980-981	6.4	2
123	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. *Nature Communications*, **2021**, 12, 117	17.4	9
122	Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.. *Journal of Clinical Oncology*, **2021**, 39, 249-249	2.2	
121	A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. *Acta Oncologica*, **2021**, 60, 1291-1295	3.2	0

120	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 682-695	4	11
119	Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. *Cancer Letters*, **2021**, 511, 56-67	9.9	5
118	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *European Urology Oncology*, **2021**, 4, 570-579	6.7	12
117	An evaluation of concordance between head and neck advanced practice radiation therapist and radiation oncologists in toxicity assessment for nasopharyngeal carcinoma patients. *Technical Innovations and Patient Support in Radiation Oncology*, **2021**, 19, 52-56	1.9	1
116	Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. *Frontiers in Oncology*, **2021**, 11, 746941	5.3	1
115	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	0
114	Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. *Clinical Oncology*, **2021**, 33, e469-e481	2.8	0
113	Recent advances in radiation therapy and photodynamic therapy. *Applied Physics Reviews*, **2021**, 8, 041322	17.3	5
112	Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. *Mikrochimica Acta*, **2021**, 189, 14	5.8	2
111	JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps.. *Cancer Communications*, **2021**,	9.4	1
110	Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia.. *Asia-Pacific Journal of Clinical Oncology*, **2021**,	1.9	2
109	Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. *BMC Cancer*, **2020**, 20, 1045	4.8	3
108	Risk of COVID-19 in Patients With Cancer-Reply. *JAMA Oncology*, **2020**, 6, 1472-1473	13.4	2
107	In Reply. *Oncologist*, **2020**, 25, e1252-e1253	5.7	
106	Follow-Up and Management of Patients With Head and Neck Cancer During the 2019 Novel Coronavirus (SARS-CoV-2) Disease Pandemic. *Advances in Radiation Oncology*, **2020**, 5, 631-636	3.3	4
105	Evolution of Cancer Care in Response to the COVID-19 Pandemic. *Oncologist*, **2020**, 25, e1426-e1427	5.7	5
104	Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma: innovation at the expense of uncertainty. *Cancer Communications*, **2020**, 40, 119-121	9.4	4
103	Four Influential Clinical Trials in Human Papilloma Virus-Associated Oropharynx Cancer. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 893-899	4	2

102	SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. *JAMA Oncology*, **2020**, 6, 1108-1110	13.4	656
101	Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts. *Advanced Science*, **2020**, 7, 1903727	13.6	4
100	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. *Oncologist*, **2020**, 25, e936-e945	5.7	356
99	A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. *Neurology*, **2020**, 95, e1392-e1403	6.5	5
98	Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. *Cancer*, **2020**, 126, 4023-4031	6.4	57
97	Electronic tumor board presentations as the basis for the development of a head and neck cancer database. *Laryngoscope Investigative Otolaryngology*, **2020**, 5, 46-54	2.8	4
96	Duration-dependent margins for prostate radiotherapy-a□practical motion mitigation strategy. *Strahlentherapie Und Onkologie*, **2020**, 196, 657-663	4.3	3
95	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. *International Journal of Cancer*, **2020**, 146, 2305-2314	7.5	19
94	A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 672-682	4	5
93	Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa).. *Journal of Clinical Oncology*, **2020**, 38, 227-227	2.2	
92	Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience. *Asia-Pacific Journal of Clinical Oncology*, **2020**, 16, 75-79	1.9	6
91	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review. *JAMA Oncology*, **2020**, 6, 567-577	13.4	20
90	The metabolic footprint during adipocyte commitment highlights ceramide modulation as an adequate approach for obesity treatment. *EBioMedicine*, **2020**, 51, 102605	8.8	2
89	Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. *Cancer Communications*, **2020**, 40, 374-379	9.4	19
88	A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study. *Diagnostics*, **2020**, 10,	3.8	12
87	Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920970050	5.4	4
86	A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. *Clinical Cancer Research*, **2020**, 26, 5438-5447	12.9	14
85	Dosimetric uncertainties impact on cell survival curve with low energy proton. *Physica Medica*, **2020** , 76, 277-284	2.7	

84	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 1345-1352	13.4	64
83	Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China. *JAMA Oncology*, **2020**, 6, 1457-1459	13.4	13
82	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. *European Urology Oncology*, **2020**,	6.7	6
81	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 70-80	4	2
80	Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. *British Journal of Radiology*, **2019**, 92, 20190271	3.4	23
79	Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. *Nature Communications*, **2019**, 10, 3941	17.4	55
78	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. *Nature Medicine*, **2019**, 25, 1615-1626	50.5	25
77	Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. *Annals of Oncology*, **2019**, 30, 637-643	10.3	21
76	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. *New England Journal of Medicine*, **2019**, 381, 1124-1135	59.2	297
75	Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. *Cancer Biology and Medicine*, **2019**, 16, 157-166	5.2	7
74	Pan-cancer analysis connects tumor matrisome to immune response. *Npj Precision Oncology*, **2019**, 3, 15	9.8	36
73	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. *Radiology*, **2019**, 291, 677-686	20.5	113
72	Widespread and Functional RNA Circularization in Localized Prostate Cancer. *Cell*, **2019**, 176, 831-843.e22	36.2	214
71	Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. *Photodiagnosis and Photodynamic Therapy*, **2019**, 27, 367-374	3.5	10
70	De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 705-709	4	11
69	Upconversion superballs for programmable photoactivation of therapeutics. *Nature Communications*, **2019**, 10, 4586	17.4	58
68	Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma. *Cancer Communications*, **2019**, 39, 64	9.4	3
67	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 46-46	2.2	1

66	Immune dysregulation underpins radioresistance in nasopharyngeal carcinoma (NPC). **2019**, 5, 52-52		1
65	Editorial Comment. *Journal of Urology*, **2019**, 201, 291	2.5	
64	The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB).. *Journal of Clinical Oncology*, **2019**, 37, 13-13	2.2	
63	The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 81-81	2.2	
62	Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 95-95	2.2	
61	A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.. *Journal of Clinical Oncology*, **2019**, 37, 6036-6036	2.2	
60	Longitudinal circulating Epstein-Barr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer.. *Journal of Clinical Oncology*, **2019**, 37, 6021-6021	2.2	
59	Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epstein-Barr virus DNA and TNM stage: A "Big data" analysis of 9,160 endemic cases.. *Journal of Clinical Oncology*, **2019**, 37, 6043-6043	2.2	
58	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 84-91	4	20
57	Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. *Annals of Oncology*, **2019**, 30, 68-75	10.3	108
56	Molecular landmarks of tumor hypoxia across cancer types. *Nature Genetics*, **2019**, 51, 308-318	36.3	255
55	Multidisciplinary team meetings - challenges of implementation science. *Nature Reviews Clinical Oncology*, **2019**, 16, 205-206	19.4	9
54	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. *Cell*, **2018**, 173, 1003-1013.e15	56.2	115
53	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 702-709	4	1
52	Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex. *FEBS Open Bio*, **2018**, 8, 15-26	2.7	9
51	Adaptive radiotherapy for head and neck cancers: Fact or fallacy to improve therapeutic ratio?. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2018**, 22, 287-295	1.3	6
50	Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma. *Chinese Clinical Oncology*, **2018**, 7, 15	2.3	21
49	A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 68-68	2.2	

48	68-Ga prostate-specific membrane antigen-PET as a diagnostic and clinical decision making tool in biochemical recurrences post-radical prostatectomy.. *Journal of Clinical Oncology*, **2018**, 36, 377-377	2.2	
47	"Cor Occidere": a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. *Chinese Clinical Oncology*, **2018**, 7, 10	2.3	
46	Retroperitoneal Knee Pain: An Unusual Case Report and Review of an Ancient Schwannoma. *Cureus*, **2018**, 10, e2216	1.2	
45	A radiomics signature for treatment stratification in advanced and recurrent nasopharynx cancer.. *Journal of Clinical Oncology*, **2018**, 36, e18060-e18060	2.2	
44	Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response.. *Journal of Clinical Oncology*, **2018**, 36, 12056-12056	2.2	
43	Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. *Journal of Clinical Oncology*, **2018**, 36, 891-899	2.2	45
42	Why we should give spatially fractionated radiation therapy (GRID) a second look especially in nasopharyngeal carcinoma. *Annals of Nasopharynx Cancer*, **2018**, 1, 1-1	0.3	0
41	Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC. *BMC Cancer*, **2018**, 18, 1095	4.8	2
40	The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma. *Cancer Biology and Medicine*, **2018**, 15, 1-5	5.2	9
39	Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. *Oral Oncology*, **2018**, 86, 61-68	4.4	8
38	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. *JAMA Oncology*, **2018**, 4, 1073-1079	13.4	26
37	Dysregulation of the MiR-449b target TGFBI alters the TGF pathway to induce cisplatin resistance in nasopharyngeal carcinoma. *Oncogenesis*, **2018**, 7, 40	6.6	23
36	Genomic hallmarks of localized, non-indolent prostate cancer. *Nature*, **2017**, 541, 359-364	50.4	320
35	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. *Radiotherapy and Oncology*, **2017**, 123, 459-465	5.3	10
34	A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. *European Urology*, **2017**, 72, 665-674	10.2	98
33	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. *Current Problems in Cancer*, **2017**, 41, 265-272	2.3	9
32	Neuropathological and transcriptomic characteristics of the aged brain. *ELife*, **2017**, 6,	8.9	50
31	Mitochondrial mutations drive prostate cancer aggression. *Nature Communications*, **2017**, 8, 656	17.4	66

30	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. *European Urology*, **2017**, 72, 22-31	10.2	28
29	Lymphocyte apoptosis as a predictive biomarker for radiotherapy de-intensification in EBV-associated nasopharynx cancer.. *Journal of Clinical Oncology*, **2017**, 35, e17545-e17545	2.2	1
28	Exploiting molecular genomics in precision radiation oncology: a marriage of biological and physical precision. *Chinese Clinical Oncology*, **2017**, 6, S19	2.3	3
27	Stereotactic body radiotherapy for early stage lung cancer-historical developments and future strategies. *Chinese Clinical Oncology*, **2017**, 6, S20	2.3	8
26	Treatment of Viral-Associated HNC (OPC and NPC) **2017**, 177-188		
25	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 42-42	2.2	
24	Genomic architecture of radioresistant prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 26-26	2.2	
23	Nasopharyngeal carcinoma. *Lancet, The*, **2016**, 387, 1012-1024	40	799
22	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. *ESMO Open*, **2016**, 1, e000123	6	3
21	Gemcitabine: a game changer in nasopharyngeal carcinoma. *Lancet, The*, **2016**, 388, 1853-1854	40	15
20	Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. *European Journal of Cancer*, **2016**, 67, 119-129	7.5	34
19	Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. *Radiotherapy and Oncology*, **2016**, 119, 244-9	5.3	9
18	Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. *Chinese Journal of Cancer*, **2016**, 35, 9		19
17	Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. *Cancer Letters*, **2016**, 374, 324-30	9.9	6
16	Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy.. *Journal of Clinical Oncology*, **2016**, 34, 101-101	2.2	
15	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 117-117	2.2	
14	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. *Journal of Clinical Oncology*, **2016**, 34, 96-96	2.2	
13	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. *Journal of Clinical Oncology*, **2016**, 34, 49-49	2.2	

12	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5051-5051	2.2	
11	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. *OncoTargets and Therapy*, **2016**, 9, 1115-22	4.4	10
10	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. *Clinical Cancer Research*, **2016**, 22, 3124-6	12.9	13
9	DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. *Radiation and Environmental Biophysics*, **2014**, 53, 355-64	2	25
8	Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. *Radiotherapy and Oncology*, **2011**, 99, 225-30	5.3	17
7	Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. *Radiotherapy and Oncology*, **2011**, 99, 362-6	5.3	47
6	Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. *Head and Neck*, **2009**, 31, 346-54	4.2	72
5	Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). *Radiation Oncology*, **2009**, 4, 23	4.2	10
4	The Uro-Oncology Multi-disciplinary team (MDT) Clinic Clinical and Patient-Reported Outcomes From Implementing a New Model of Care. *Proceedings of Singapore Healthcare*,201010582110552	0.5	
3	SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan		42
2	Infection Control of 2019 Novel Corona Virus Disease (COVID-19) in Cancer Patients undergoing Radiotherapy in Wuhan		2
1	A Multicenter Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China		9